FDA stings thousands of fake drug sites
The US Food and Drug Administration (FDA) last month seized and shut down 1,677 illegal pharmacy websites selling $41,104,386 worth of fake medicines.
Novartis strikes vaccine licensing deal with Indian biopharma
Novartis has signed a development and licensing agreement with Indian biopharmaceutical company Biological E Limited (BioE) to deliver two vaccines that protect against typhoid and paratyphoid fevers.
EU court overrules commission in Orphacol drug case
The General Court of the European Union has annulled the European Commission’s decision to refuse marketing authorisation for orphan drug Orphacol.
UCB challenges Teva generic drug application
Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
AbbVie triumphs in Humira case
Pharmaceutical company AbbVie has won a patent case against UK research body The Kennedy Institute of Rheumatology Trust relating to the arthritis medication Humira.
Merck wins injunction in sitagliptin patent row
Pharmaceutical company Merck has secured a preliminary injunction against Indian drug company Aprica after it tried to market generic versions of the branded diabetes drug Januvia.
Generics swoop as Viagra patent expires
Global drug companies Actavis and Teva both launched generic versions of Viagra immediately after its patent expired in several European countries last week.
Federal Circuit holds Novo Nordisk patent invalid
The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.
European Commission targets alleged ‘pay-for-delay’ with pharma fines
The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.
US Supreme Court backs ‘rule-of-reason’ for pay-for-delay
A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
